Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion (MpeTK01)
A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Sponsor: Candel Therapeutics, Inc.
This PHASE1 trial investigates Breast Cancer and Lung Cancer and is currently completed. Candel Therapeutics, Inc. leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Sep 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
Apr 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Candel Therapeutics, Inc.
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .